Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of setmelanotide in rare genetic, syndromic, or acquired MC4R pathway diseases
2026-000402-34Phase 4
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Oct 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of setmelanotide in Melanocortin-4 receptor deficiency (MC4RD), syndromic obesity and Acquired Hypothalamic Obesity (aHO), sponsored by Rhythm Pharmaceuticals. Primary endpoints: Frequency and severity of adverse events, Physical examination changes and 2 more.
02
Drugs
setmelanotide
03
Conditions
Melanocortin-4 receptor deficiency (MC4RD)syndromic obesityAcquired Hypothalamic Obesity (aHO)
Beyond the preview
Go deeper on 2026-000402-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-000402-34.